ReviewMedical oncology (Northwood, London, England)2024
The treatment landscape of triple-negative breast cancer.
Review in Medical oncology (Northwood, London, England), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed.
- Ionomycin enhances radiosensitivity in breast cancer through reactive oxygen species generation and mitochondrial permeability transition pore opening.Medical gas research · 2026Article
- Article
- Long Noncoding RNAs (lncRNAs) as Biomarkers of Prognosis in TNBC and Non-TNBC Breast Cancer Patients.International journal of molecular sciences · 2026Article
- Combine antibody-drug conjugate with cmLumiOpto for triple-negative breast cancer treatment.Cell reports. Medicine · 2026Article
- CDCA4 Promotes Lipid Metabolism in Triple-Negative Breast Cancer Through Activation of the SESN2/mTOR/SREBP1 Pathway.Cancers · 2026Article
- CHD6 promotes triple-negative breast cancer progression and is associated with PI3K/AKT and MAPK pathways.International journal of clinical oncology · 2026Article
- Efficacy and Safety of Shen-Ling-Lian-Xia Granule Combined With Neoadjuvant Chemotherapy in Patients With Triple-Negative Breast Cancer: Protocol for a Randomized, Double-Blind, Multicenter Clinical Trial.JMIR research protocols · 2026Article
- Peptide-mediated immunomodulation of tumor microenvironment in triple-negative breast cancer: A comprehensive review.The Journal of pharmacology and experimental therapeutics · 2026Review
- CXCL1 in triple‑negative breast cancer: Mechanisms, challenges, and therapeutic opportunities (Review).Oncology reports · 2026Review
- Design, Synthesis and Evaluation of Anticancer Potential of Novel Pyrrolopyrazines Against Glioblastoma: Mechanistic Details and In Vivo Safety Analysis.Archiv der Pharmazie · 2026Article
- Targeting Triple-Negative Breast Cancer: A Special Focus on Phototherapy and Nanomaterials.Molecules (Basel, Switzerland) · 2026Review
- Impact of androgen receptor on triple negative breast cancer: a systematic review and meta-analytic study.BMJ public health · 2026Article
- A Pan-Subtype Fatty Acid Metabolic Signature Reveals Universal Prognostic Stratification in Breast Cancer.Cancer reports (Hoboken, N.J.) · 2026Article
- Integrative analysis ofFrontiers in pharmacology · 2026Article
- How has the field of immunogenic cell death in breast cancer evolved and impacted clinical practice over the past eleven years?Human vaccines & immunotherapeutics · 2025Review
- Combined XPO1 Inhibition and Parthenolide Treatment Can Be Efficacious in Treating Triple-Negative Breast Cancer.International journal of molecular sciences · 2025Article
- Profiling the Expression Level of a Gene from the Caspase Family in Triple-Negative Breast Cancer.International journal of molecular sciences · 2025Article
- New Chemotherapeutic Approaches to Treatment of Mesenchymal Triple-Negative Breast Cancer-Sensitive and Resistant to Cisplatin: Assessment of Cellular Response by Vibrational Microspectroscopy.Analytical chemistry · 2025Article
- Review
- Machine learning and single-cell analysis uncover distinctive characteristics of CD300LG within the TNBC immune microenvironment: experimental validation.Clinical and experimental medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Triple-negative breast cancer (TNBC) tumors are biologically aggressive breast cancer. On the molecular level, TNBC is a highly heterogeneous disease; more biotechnologies are gradually being used to advance the understanding of TNBC subtypes and help establish more targeted therapies. Multiple TNBC target-related agents are already approved by the Food and Drug Administration for clinical use, including PI3K/AKT/mTOR inhibitors, PRAP inhibitors, and antibody-drug conjugates. Some innovative approaches, like peptide strategies, also promise to treat TNBC. Currently, the interplay between TNBC tumors and their tumor microenvironment provides a promising prospect for improving the efficacy of immunotherapy. In this review, we summarize the prevalent TNBC subtype methodologies, discuss the evolving therapeutic strategies, and propose new therapeutic possibilities based on existing foundational theories, with the attempt to serve as a reference to further advance tailoring treatment of TNBC.
Indexed as
Identifiers
39210220What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.